Paradigm Biopharmaceuticals Balance Sheet Health
Financial Health criteria checks 4/6
Paradigm Biopharmaceuticals has a total shareholder equity of A$23.8M and total debt of A$0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are A$27.4M and A$3.6M respectively.
Key information
0%
Debt to equity ratio
AU$0
Debt
| Interest coverage ratio | n/a |
| Cash | AU$17.87m |
| Equity | AU$23.81m |
| Total liabilities | AU$3.58m |
| Total assets | AU$27.39m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: PBIG.F's short term assets (A$24.3M) exceed its short term liabilities (A$3.4M).
Long Term Liabilities: PBIG.F's short term assets (A$24.3M) exceed its long term liabilities (A$224.5K).
Debt to Equity History and Analysis
Debt Level: PBIG.F is debt free.
Reducing Debt: PBIG.F has no debt compared to 5 years ago when its debt to equity ratio was 0.04%.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: PBIG.F has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: PBIG.F has less than a year of cash runway if free cash flow continues to reduce at historical rates of 37.6% each year